Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. Chief Executive Officer James Nathaniel Powell reported a routine tax-related transaction in the company’s Class A common stock. On 01/02/2026, 2,464 shares were withheld at a price of $0.593 per share to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award.
After this withholding, Powell beneficially owned 125,593 shares of Longeveron Class A common stock on a direct basis, which includes RSUs that remain subject to future vesting.
Longeveron Inc. (LGVN) reported that two directors, Khoso Baluch and Neha Motwani, resigned from the Board of Directors, effective immediately on November 7, 2025.
The company stated the resignations were not due to any disagreement regarding its operations, policies, practices, management, or Board. The report was signed by Interim CEO Than Powell.
Longeveron Inc. furnished an 8‑K announcing it issued a press release with financial and operating results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1. The Company states the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
Longeveron Inc. reported Q3 2025 results marked by much lower revenue and a wider loss as the company advances its lead cell therapy program. Total revenue was $137k for the quarter, down from $773k a year ago, reflecting a sharp decline in contract manufacturing activity. Net loss was $7.221M versus $4.419M in Q3 2024.
Cash and cash equivalents were $9.244M as of September 30, 2025. Management states this should fund operations late into Q1 2026 based on the current plan, and it has an ATM facility up to $10.7M in aggregate market value. The filing notes substantial doubt about the company’s ability to continue as a going concern without additional financing.
For the nine months ended September 30, 2025, revenue was $834k (vs. $1.789M in 2024) and net loss was $17.260M (vs. $11.892M). Operating expenses rose, with R&D at $9.321M and G&A at $9.113M. The company is prioritizing its HLHS program and anticipates a potential BLA filing in 2027 if the current ELPIS II trial is successful. As of October 31, 2025, shares outstanding were 19,848,876 Class A and 1,484,005 Class B.
Longeveron Inc. (LGVN) reported an insider equity award. A director acquired 34,000 shares of Class A common stock on 10/01/2025, recorded at a $0 price, as part of a time-based vesting RSU award.
Following the transaction, the reporting person beneficially owned 34,000 shares, held directly. The filing notes the holdings include RSUs subject to future vesting.
Longeveron (LGVN): A reporting person serving as a director filed an initial Form 3. The filing states no securities are beneficially owned, with Table I showing Class A Common Stock: 0 and no derivative securities listed. The date of the event requiring the statement is 10/01/2025. The submission includes a Power of Attorney, with the form signed by an attorney-in-fact.
Nataliya Agafonova, Chief Medical Officer of Longeveron Inc. (LGVN), reported a transaction dated 10/01/2025 on Form 4 showing a sale of 11,883 shares of Class A common stock at a price of $0.7424 per share.
After the reported disposition, the filing shows Agafonova beneficially owns 226,814 shares, which the filer states includes restricted stock units (RSUs) subject to future vesting. The filing also explains that 11,883 shares were withheld to satisfy tax obligations arising from the vesting of an RSU award.
Longeveron (LGVN) CEO reported a routine insider transaction on a Form 4. On 10/01/2025, 2,389 shares of Class A common stock were withheld at $0.7424 to cover taxes upon the vesting of a restricted stock unit award. Following this tax withholding, the reporting person beneficially owned 128,057 shares. The filing notes the balance includes RSUs subject to future vesting.
Longeveron Inc. (LGVN) reported an insider transaction by its General Counsel and Secretary. On 10/01/2025, the officer had 4,944 shares of Class A common stock withheld to cover taxes upon RSU vesting (transaction code F) at $0.7424 per share.
Following the transaction, the officer beneficially owns 351,129 shares directly. The holding includes RSUs subject to future vesting, as noted in the footnotes.
Longeveron (LGVN) reported an insider equity transaction by its CTO & SVP of CMC. On 10/01/2025, the officer had 7,609 shares of Class A common stock withheld under transaction code F to cover taxes upon the vesting of a restricted stock unit (RSU) award at a price of $0.7424 per share. Following this tax withholding, the officer beneficially owned 210,876 shares, which includes RSUs subject to future vesting.